Novel agents in the treatment of lung cancerLYNCH, Thomas J; JÄNNE, Pasi A; GURUBHAGAVATULA, Sarada et al.Clinical cancer research. 2004, Vol 10, Num 12, issn 1078-0432, 92 p., 2Conference Proceedings

Novel agents in the treatment of lung cancer: Conference summary statementLYNCH, Thomas J; ADJEI, Alex A; PEREZ-SOLER, Roman et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4199s-4204s, issn 1078-0432, 2Conference Paper

Novel agents in the treatment of lung cancer : Fourth cambridge conferenceLYNCH, Thomas J; BONOMI, Philip D; PEREZ-SOLER, Roman et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4583s-4586s, 2Conference Paper

Novel agents in the treatment of lung cancer: proceedings of the fourth Cambridge ConferenceLYNCH, Thomas J; GURUBHAGAVATULA, Sarada; JACKMAN, David et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 79 p., 2Conference Proceedings

Cyclooxygenase as a target in lung cancerBROWN, Joanne R; DUBOIS, Raymond N.Clinical cancer research. 2004, Vol 10, Num 12, pp 4266s-4269s, issn 1078-0432, 2Conference Paper

The role of gefitinib in lung cancer treatmentGIACCONE, Giuseppe.Clinical cancer research. 2004, Vol 10, Num 12, pp 4233s-4237s, issn 1078-0432, 2Conference Paper

Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibitionGANDARA, David R; WEST, Howard; CHANSKY, Kari et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4205s-4209s, issn 1078-0432, 2Conference Paper

Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancerSANDLER, Alan B; JOHNSON, David H; HERBST, Roy S et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4258s-4262s, issn 1078-0432, 2Conference Paper

The biology of epidermal growth factor receptor in lung cancerSCAGLIOTTI, Giorgio V; SELVAGGI, Giovanni; NOVELLO, Silvia et al.Clinical cancer research. 2004, Vol 10, Num 12, pp 4227s-4232s, issn 1078-0432, 2Conference Paper

Molecularly targeted approaches to the chemoprevention of lung cancerKHURI, Fadlo R; COHEN, Victor.Clinical cancer research. 2004, Vol 10, Num 12, pp 4249s-4253s, issn 1078-0432, 2Conference Paper

Farnesyl transferase inhibitors for patients with lung cancerJOHNSON, Bruce E; HEYMACH, John V.Clinical cancer research. 2004, Vol 10, Num 12, pp 4254s-4257s, issn 1078-0432, 2Conference Paper

Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agentADJEI, Alex A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4276s-4280s, issn 1078-0432, 2Conference Paper

The potential role of proteasome inhibitors in the treatment of lung cancerBUNN, Paul A.Clinical cancer research. 2004, Vol 10, Num 12, pp 4263s-4265s, issn 1078-0432, 2Conference Paper

Incorporating bortezomib into the treatment of lung cancer. DiscussionDAVIES, Angela M; LARA, Primo N; MACK, Philip C et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4647s-4651s, 2Conference Paper

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridolSHAPIRO, Geoffrey I.Clinical cancer research. 2004, Vol 10, Num 12, pp 4270s-4275s, issn 1078-0432, 2Conference Paper

Clinical trial design issues in the era of targeted therapiesSCHILLER, Joan H.Clinical cancer research. 2004, Vol 10, Num 12, pp 4281s-4282s, issn 1078-0432, 2Conference Paper

Bevacizumab in non-small cell lung cancer. DiscussionSANDLER, Alan; LYNCH, Thomas; HERBST, Roy et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4613s-4616s, 2Conference Paper

Cetuximab in advanced non-small cell lung cancerGOVINDAN, Ramaswamy.Clinical cancer research. 2004, Vol 10, Num 12, pp 4241s-4244s, issn 1078-0432, 2Conference Paper

Is there a role for cetuximab in non-small cell lung cancer? DiscussionMORGENSZTERN, Daniel; GOVINDAN, Ramaswamy; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4602s-4605s, 2Conference Paper

Vascular endothelial growth factor trap in non-small cell lung cancer. DiscussionRIELY, Gregory J; MILLER, Vincent A; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4623s-4627s, 2Conference Paper

HKI-272 in non-small cell lung cancer. DiscussionWONG, Kwok-Kin; LYNCH, Thomas; ENGELMAN, Jeffrey et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4593s-4596s, 2Conference Paper

Novel agents in the treatment of lung cancer: advances in EGFR-targeted agents: Proceedings of the Third Cambridge Conference, Cambridge, Massachusetts, September 23-24, 2005LYNCH, Thomas J; ENGELMAN, Jeffrey A; EVANS, Tracey L et al.Clinical cancer research. 2006, Vol 12, Num 14, issn 1078-0432, 100 p., 2Conference Proceedings

Oblimersen sodium (genasense bcl-2 antisense oligonucleotide): A rational therapeutic to enhance apoptosis in therapy of lung cancerHERBST, Roy S; FRANKEL, Stanley R.Clinical cancer research. 2004, Vol 10, Num 12, pp 4245s-4248s, issn 1078-0432, 2Conference Paper

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancerPEREZ-SOLER, Roman.Clinical cancer research. 2004, Vol 10, Num 12, pp 4238s-4240s, issn 1078-0432, 2Conference Paper

The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. DiscussionENGELMAN, Jeffrey A; PEREZ-SOLER, Roman; LYNCH, Thomas et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4637s-4640s, 2Conference Paper